Reviva Pharmaceuticals Holdings, Inc. financial data

Symbol
RVPH, RVPHW on Nasdaq
Industry
Pharmaceutical Preparations
Location
10080 N Wolfe Road, Suite Sw3 200, Cupertino, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Tenzing Acquisition Corp. (to 12/14/2020)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -450 % -376%
Return On Assets -284 % -41.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.8M shares +31.6%
Common Stock, Shares, Outstanding 29.8M shares +31.6%
Entity Public Float 104M USD
Common Stock, Value, Issued 2.98K USD +31.7%
Weighted Average Number of Shares Outstanding, Basic 30.6M shares +36.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 29M USD +10.6%
General and Administrative Expense 8.19M USD +12%
Operating Income (Loss) -37.2M USD -10.9%
Nonoperating Income (Expense) 1.26M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -36M USD -5.5%
Income Tax Expense (Benefit) 22.3K USD +13.6%
Net Income (Loss) Attributable to Parent -36M USD -5.51%
Earnings Per Share, Basic -1.33 USD/shares +16.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.18M USD -44.6%
Assets, Current 7.23M USD
Assets 8.05M USD -32%
Accounts Payable, Current 4.69M USD +77.2%
Employee-related Liabilities, Current 1.3M USD
Liabilities, Current 13.9M USD +10.3%
Liabilities 14.1M USD +3.2%
Retained Earnings (Accumulated Deficit) -150M USD -31.7%
Stockholders' Equity Attributable to Parent -6.04M USD -233%
Liabilities and Equity 8.05M USD -32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.7M USD -47.5%
Net Cash Provided by (Used in) Financing Activities 332K USD -51.7%
Common Stock, Shares Authorized 115M shares 0%
Common Stock, Shares, Issued 29.8M shares +31.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.49K USD
Deferred Tax Assets, Valuation Allowance 27.5M USD +58.7%
Deferred Tax Assets, Gross 27.5M USD +58.7%
Depreciation 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 15.3M USD +20.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Additional Paid in Capital 144M USD +28.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.47M USD -47%
Interest Expense 3.49K USD -54.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares